{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:03:11Z","timestamp":1788346991610,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T00:00:00Z","timestamp":1352332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s12185-012-1215-6","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T19:19:04Z","timestamp":1352315944000},"page":"685-691","source":"Crossref","is-referenced-by-count":18,"title":["Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?"],"prefix":"10.1007","volume":"96","author":[{"given":"Carmelo","family":"Caldarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Isgr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,8]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324\u201339.","journal-title":"Lancet"},{"key":"1215_CR2","first-page":"815013","volume":"2011","author":"ZA Issa","year":"2011","unstructured":"Issa ZA, Zantout MS, Azar ST. Multiple myeloma and diabetes. ISRN Endocrinol. 2011;2011:815013.","journal-title":"ISRN Endocrinol"},{"key":"1215_CR3","first-page":"89","volume":"105","author":"EA Coleman","year":"2008","unstructured":"Coleman EA, Senner JW, Edwards BK. Does multiple myeloma incidence vary by geographic area? J Ark Med Soc. 2008;105:89\u201391.","journal-title":"J Ark Med Soc"},{"key":"1215_CR4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/annonc\/mdq370","volume":"21","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010;21:143\u201350.","journal-title":"Ann Oncol"},{"key":"1215_CR5","first-page":"1060","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1060\u201377.","journal-title":"N Engl J Med"},{"key":"1215_CR6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3322\/canjclin.48.1.6","volume":"48","author":"SH Landis","year":"1998","unstructured":"Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6\u201329.","journal-title":"CA Cancer J Clin"},{"key":"1215_CR7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749\u201357.","journal-title":"Br J Haematol"},{"key":"1215_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3\u20139.","journal-title":"Leukemia"},{"key":"1215_CR9","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"1215_CR10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"1215_CR11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00330-007-0738-3","volume":"18","author":"P Kr\u00f6pil","year":"2008","unstructured":"Kr\u00f6pil P, Fenk R, Fritz LB, Blondin D, Kobbe G, M\u00f6dder U, et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008;18:51\u20138.","journal-title":"Eur Radiol"},{"key":"1215_CR12","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/cncr.26467","volume":"118","author":"D Lammeren-Venema van","year":"2012","unstructured":"van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegeman S, Hoekstra OS, Zijlstra JM. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118:1971\u201381.","journal-title":"Cancer"},{"key":"1215_CR13","doi-asserted-by":"crossref","unstructured":"Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012. doi: 10.1111\/bjh.12007 .","DOI":"10.1111\/bjh.12007"},{"key":"1215_CR14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2967\/jnumed.107.045641","volume":"49","author":"R Fonti","year":"2008","unstructured":"Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, et al. 18F-FDG PET\/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49:195\u2013200.","journal-title":"J Nucl Med"},{"key":"1215_CR15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00259-005-0004-3","volume":"33","author":"C Nanni","year":"2006","unstructured":"Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1215_CR16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.rlu.0000178027.20780.95","volume":"30","author":"K Wang","year":"2005","unstructured":"Wang K, Allen L, Fung E, Chan CC, Chan JC, Griffith JF. Bone scintigraphy in common tumors with osteolytic components. Clin Nucl Med. 2005;30:655\u201371.","journal-title":"Clin Nucl Med"},{"key":"1215_CR17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","volume":"37","author":"YY Lu","year":"2012","unstructured":"Lu YY, Chen JH, Lin WY, Liang JA, Wang HY, Tsai SC, et al. FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37:833\u20137.","journal-title":"Clin Nucl Med"},{"key":"1215_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00259-001-0711-3","volume":"29","author":"H Schirrmeister","year":"2002","unstructured":"Schirrmeister H, Bommer M, Buck AK, M\u00fcller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:361\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1215_CR19","first-page":"1457","volume":"43","author":"BG Durie","year":"2002","unstructured":"Durie BG, Waxman AD, D\u2019Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457\u201363.","journal-title":"J Nucl Med"},{"key":"1215_CR20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","volume":"38","author":"R Haznedar","year":"2011","unstructured":"Haznedar R, Ak\u0131 SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Ya\u011fc\u0131 M, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1215_CR21","first-page":"1208","volume":"38","author":"AM El-Shirbiny","year":"1997","unstructured":"El-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med. 1997;38:1208\u201310.","journal-title":"J Nucl Med"},{"key":"1215_CR22","first-page":"32","volume":"13","author":"GL Cascini","year":"2010","unstructured":"Cascini GL, Cuccurullo V, Tamburrini O, Mansi L, Rotondo A. Nuclear medicine in multiple myeloma\u2014more than diagnosis. Nucl Med Rev Cent East Eur. 2010;13:32\u20138.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"1215_CR23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","volume":"184","author":"MA Bredella","year":"2005","unstructured":"Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184:1199\u2013204.","journal-title":"AJR Am J Roentgenol"},{"key":"1215_CR24","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00277-009-0829-0","volume":"88","author":"S L\u00fctje","year":"2009","unstructured":"L\u00fctje S, de Rooy JW, Croockewit S, Koedam E, Oyen WJ, Raymakers RA. Role of radiography, MRI and FDG-PET\/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol. 2009;88:1161\u20138.","journal-title":"Ann Hematol"},{"key":"1215_CR25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.biopha.2012.06.004","volume":"66","author":"L Evangelista","year":"2012","unstructured":"Evangelista L, Panunzio A, Polverosi R, Ferretti A, Chondrogiannis S, Pomerri F, et al. Early bone marrow metastasis detection: the additional value of FDG-PET\/CT vs CT imaging. Biomed Pharmacother. 2012;66:448\u201353.","journal-title":"Biomed Pharmacother"},{"key":"1215_CR26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","volume":"92","author":"E Zamagni","year":"2007","unstructured":"Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50\u20135.","journal-title":"Haematologica"},{"key":"1215_CR27","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2214\/AJR.08.1633","volume":"192","author":"CP Shortt","year":"2009","unstructured":"Shortt CP, Gleeson TG, Breen KA, McHugh J, O\u2019Connell MJ, O\u2019Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009;192:980\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"1215_CR28","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376.","journal-title":"Blood"},{"key":"1215_CR29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ijrobp.2008.08.037","volume":"74","author":"PJ Kim","year":"2009","unstructured":"Kim PJ, Hicks RJ, Wirth A, Ryan G, Seymour JF, Prince HM, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009;74:740\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1215_CR30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00256-010-1088-9","volume":"40","author":"S Sager","year":"2011","unstructured":"Sager S, Erg\u00fcl N, Ciftci H, Cetin G, G\u00fcner SI, Cermik TF. The value of FDG PET\/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skeletal Radiol. 2011;40:843\u20137.","journal-title":"Skeletal Radiol"},{"key":"1215_CR31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00259-011-1993-8","volume":"39","author":"T Derlin","year":"2012","unstructured":"Derlin T, Weber C, Habermann CR, Herrmann J, Wisotzki C, Ayuk F, et al. 18F-FDG PET\/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39:493\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1215_CR32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1215_CR33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00256-002-0580-2","volume":"31","author":"H Jadvar","year":"2002","unstructured":"Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiplemyeloma. Skeletal Radiol. 2002;31:690\u20134.","journal-title":"Skeletal Radiol"},{"key":"1215_CR34","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989\u201395.","journal-title":"Blood"},{"key":"1215_CR35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"B Barlogie","year":"2007","unstructured":"Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176\u201385.","journal-title":"Br J Haematol"},{"key":"1215_CR36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/RLU.0b013e3181b06bc5","volume":"34","author":"A Dimitrakopoulou-Strauss","year":"2009","unstructured":"Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss LG. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34:576\u201384.","journal-title":"Clin Nucl Med"},{"key":"1215_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.0902-4441.2004.00177.x","volume":"72","author":"L Mileshkin","year":"2004","unstructured":"Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol. 2004;72:32\u20137.","journal-title":"Eur J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1215-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1215-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1215-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:08Z","timestamp":1559452268000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1215-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,8]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1215-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,8]]}}}